Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18489046 | 1.00 | ADORA2A (0.44) | ADORA2AADORA2BADORA3LMNACYP1A2 | |
| SCHEMBL18489048 | 1.00 | ADORA2A (0.44) | ADORA2AADORA2BADORA3LMNACYP1A2 | |
| SCHEMBL18482696 | 1.00 | ADORA2A (0.44) | ADORA2AADORA2BADORA3LMNACYP1A2 | |
| SCHEMBL18482643 | 1.00 | ADORA2A (0.44) | ADORA2AADORA2BADORA3LMNACYP1A2 | |
| SCHEMBL18760503 | 1.00 | ADORA2A (0.44) | ADORA2AADORA2BADORA3LMNACYP1A2 | |
| SCHEMBL16082062 | 0.72 | ADORA2A (0.38) | ADORA2AADORA2BADORA3LMNACYP1A2 | |
| SCHEMBL1120502 | 0.71 | ADORA2B (0.49) | ADORA2AADORA2BADORA3LMNACYP1A2 | |
| SCHEMBL16059650 | 0.68 | HCAR2 (0.35) | ADORA2AADORA2BADORA3LMNACYP1A2 | |
| SCHEMBL6934888 | 0.65 | KDM4E (0.42) | ADORA2AADORA2BADORA3LMNACYP1A2 | |
| SCHEMBL762514 | 0.65 | NPC1 (0.47) | ADORA2AADORA2BADORA3LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751863-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170037031-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037031-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, BRDT, TP53 | ADORA2A 1945/4885ADORA2B 3483/4885ADORA3 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.